Lisdexamfetamine Dimesylate: uses, dosing, side effects & brands

Arynta (Lisdexamfetamine Dimesylate) is a central nervous system stimulant used to treat Attention Deficit Disorder with Hyperactivity, Binge Drinking.

The FDA classifies lisdexamfetamine dimesylate as a central nervous system stimulant. CNS stimulants raise the levels of the brain's signaling chemicals dopamine and norepinephrine, either by releasing more of them or by blocking their reuptake. This heightened activity in attention and arousal circuits increases alertness, energy, and focus. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The elimination half-life of lisdexamfetamine dimesylate is less than 1 hour (parent drug) — that is how long the body takes to clear half of a dose. Lisdexamfetamine is an inactive prodrug: the parent's own elimination half-life is under 1 hour and it is essentially undetectable in blood by 8 hours. The clinically meaningful effect comes from its active metabolite, dextroamphetamine, which has a much longer elimination half-life of about 10 to 11 hours in healthy adults (about 8.6 to 9.5 hours in children 6 to 12). Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run lisdexamfetamine dimesylate against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 3 lisdexamfetamine dimesylate-containing products in the U.S.: Arynta, Lisdexamfetamine Dimesylate and Vyvanse. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, lisdexamfetamine dimesylate is currently marketed as solution, capsule and tablet, chewable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic lisdexamfetamine dimesylate product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists at least 5 recall records whose product description mentions lisdexamfetamine dimesylate. The most recent: Lisdexamfetamine Dimesylate Capsules (Oct 28, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

"In your system" means two different things, and Vyvanse is unusual because it is a prodrug. Lisdexamfetamine itself is inactive and is rapidly converted in the body to dextroamphetamine, which does the work; the parent prodrug has a very short half-life (under about 1 hour), while the active dextroamphetamine has a half-life of roughly 10 to 12 hours in adults, per the FDA prescribing information. Because a drug is largely eliminated after about 4 to 5 half-lives, most of a single dose is cleared in roughly 2 to 3 days. Second is detectability: a drug test detects the resulting amphetamine, not the prodrug, and how long depends on the test type. These are approximate ranges from laboratory and pharmacology references, not guarantees, and only a clinician or testing lab can interpret a specific result.

Urine is the most common test. Because lisdexamfetamine is converted to dextroamphetamine in the body, it is detected as amphetamine, and a standard amphetamine immunoassay WILL register it (unlike methylphenidate, which does not). Mayo Clinic Laboratories and ARUP list amphetamine urine detection at roughly 1 to 3 days for a therapeutic dose, sometimes up to about a week with heavy or repeated use. The exact window depends on the dose, how long and how often it was taken, individual metabolism, hydration, urine pH, and the specific assay and cutoff. Urine pH is one of the individual factors that can shift the amphetamine window, which is part of why these ranges vary from person to person. These are approximate ranges; only the testing lab can interpret an actual result.

Because Vyvanse is detected as dextroamphetamine, its windows mirror amphetamine. In blood, amphetamine is typically detectable for about 24 to 48 hours (occasionally up to roughly 2 to 3 days). In saliva (oral fluid) it can appear within about 20 minutes of dosing and generally remains detectable for up to around 1 to 2 days. Hair testing has by far the longest window: a standard hair-strand test can reflect amphetamine use for up to about 90 days, because the drug is deposited in growing hair. All of these are approximate laboratory ranges that vary with dose, frequency of use, metabolism, and the assay. This information is factual and educational only; it is not advice about passing or altering a test, and no one should stop a prescribed medication without talking to the prescribing clinician.